Cargando…

2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study

BACKGROUND: There are fewer board-certified infectious disease (ID) specialists in Japan (n = 1494) than in the United States (n = 8535); therefore, we have insufficient protected time for antimicrobial stewardship activities, and thus, there is a need for an innovative solution. METHODS: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Matono, Takashi, Uchida, Moritsugu, Koga, Hidenobu, Kanatani, Naoya, Furuno, Yoshimi, Yamashita, Tomonori, PharmD, Yuichi Umeda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808984/
http://dx.doi.org/10.1093/ofid/ofz360.1721
_version_ 1783461871821520896
author Matono, Takashi
Uchida, Moritsugu
Koga, Hidenobu
Kanatani, Naoya
Furuno, Yoshimi
Yamashita, Tomonori
PharmD, Yuichi Umeda,
author_facet Matono, Takashi
Uchida, Moritsugu
Koga, Hidenobu
Kanatani, Naoya
Furuno, Yoshimi
Yamashita, Tomonori
PharmD, Yuichi Umeda,
author_sort Matono, Takashi
collection PubMed
description BACKGROUND: There are fewer board-certified infectious disease (ID) specialists in Japan (n = 1494) than in the United States (n = 8535); therefore, we have insufficient protected time for antimicrobial stewardship activities, and thus, there is a need for an innovative solution. METHODS: This study compared carbapenem consumption between a 24-month baseline period and a 12-month intervention period at the Iizuka Hospital with 1048 inpatient beds in Japan. During the intervention period, a board-certified ID specialist provided daily feedback to prescribers against prolonged carbapenem use (≥14 days) through conversations and medical records. Additionally, we reported through e-mail the weekly point prevalence surveillance data of the long-term carbapenem users for 7–13 and ≥14 days, which were aggregated by each department. RESULTS: We provided a total of 106 feedbacks regarding carbapenem use for ≥14 days during the intervention period. After the initiation of intervention, the trend of monthly carbapenem consumption changed (coefficient: −0.62; 95% CI: −1.15 to −0.087, P = 0.024), and its overall consumption has decreased (coefficient: −0.098; 95% CI: −0.16 to −0.039, P = 0.002, Figure 1) without a change in the in-hospital mortality (P = 0.53) as revealed by segmented regression analysis. Interestingly, the number of monthly carbapenem users, but not the duration of carbapenem use, significantly decreased (coefficient: −3.02; 95% CI: −4.63 to −1.42, P = 0.001, Figure 2). An annual estimated saving after the intervention was $82,266 with a cost reduction of 22%. CONCLUSION: Our ID specialist-led daily intervention in carbapenem prescription and weekly feedback for long-term carbapenem use were effective in reducing this antibiotic’s consumption and consequently the number of carbapenem users. These feedbacks may be useful in changing the behavior of prescribers and promoting appropriate antimicrobial use even in resource-poor settings. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6808984
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68089842019-10-28 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study Matono, Takashi Uchida, Moritsugu Koga, Hidenobu Kanatani, Naoya Furuno, Yoshimi Yamashita, Tomonori PharmD, Yuichi Umeda, Open Forum Infect Dis Abstracts BACKGROUND: There are fewer board-certified infectious disease (ID) specialists in Japan (n = 1494) than in the United States (n = 8535); therefore, we have insufficient protected time for antimicrobial stewardship activities, and thus, there is a need for an innovative solution. METHODS: This study compared carbapenem consumption between a 24-month baseline period and a 12-month intervention period at the Iizuka Hospital with 1048 inpatient beds in Japan. During the intervention period, a board-certified ID specialist provided daily feedback to prescribers against prolonged carbapenem use (≥14 days) through conversations and medical records. Additionally, we reported through e-mail the weekly point prevalence surveillance data of the long-term carbapenem users for 7–13 and ≥14 days, which were aggregated by each department. RESULTS: We provided a total of 106 feedbacks regarding carbapenem use for ≥14 days during the intervention period. After the initiation of intervention, the trend of monthly carbapenem consumption changed (coefficient: −0.62; 95% CI: −1.15 to −0.087, P = 0.024), and its overall consumption has decreased (coefficient: −0.098; 95% CI: −0.16 to −0.039, P = 0.002, Figure 1) without a change in the in-hospital mortality (P = 0.53) as revealed by segmented regression analysis. Interestingly, the number of monthly carbapenem users, but not the duration of carbapenem use, significantly decreased (coefficient: −3.02; 95% CI: −4.63 to −1.42, P = 0.001, Figure 2). An annual estimated saving after the intervention was $82,266 with a cost reduction of 22%. CONCLUSION: Our ID specialist-led daily intervention in carbapenem prescription and weekly feedback for long-term carbapenem use were effective in reducing this antibiotic’s consumption and consequently the number of carbapenem users. These feedbacks may be useful in changing the behavior of prescribers and promoting appropriate antimicrobial use even in resource-poor settings. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808984/ http://dx.doi.org/10.1093/ofid/ofz360.1721 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Matono, Takashi
Uchida, Moritsugu
Koga, Hidenobu
Kanatani, Naoya
Furuno, Yoshimi
Yamashita, Tomonori
PharmD, Yuichi Umeda,
2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title_full 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title_fullStr 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title_full_unstemmed 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title_short 2041. Impact of an Infectious Disease Specialist-led Post-Prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before–After Cohort Study
title_sort 2041. impact of an infectious disease specialist-led post-prescription carbapenem intervention in a large japanese tertiary hospital: a before–after cohort study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808984/
http://dx.doi.org/10.1093/ofid/ofz360.1721
work_keys_str_mv AT matonotakashi 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT uchidamoritsugu 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT kogahidenobu 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT kanataninaoya 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT furunoyoshimi 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT yamashitatomonori 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy
AT pharmdyuichiumeda 2041impactofaninfectiousdiseasespecialistledpostprescriptioncarbapeneminterventioninalargejapanesetertiaryhospitalabeforeaftercohortstudy